Prevencio wins fourth AMA CPT code for HART PAD test

Prevencio said the American Medical Association granted a proprietary CPT billing code for its HART PAD blood test, giving the AI-powered peripheral artery disease test a stronger reimbursement path. The move marks the company’s fourth AMA-issued code and expands the commercial footing of its HART diagnostics platform.

Why it matters: - The new billing code can make the HART PAD blood test easier for doctors and labs to bill, which matters for reimbursement and adoption. - Peripheral artery disease is common, underdiagnosed, and tied to heart attack, stroke, limb loss, and cardiovascular death. - Earlier detection can support faster treatment and more targeted follow-up care.

What happened: - Prevencio said the American Medical Association granted a Proprietary Laboratory Analyses Current Procedural Terminology billing code for HART PAD. - The announcement was made July 14, 2026. - The code is Prevencio’s fourth AMA-issued proprietary CPT code. - HART PAD is an AI-powered, multiprotein blood test designed to help detect obstructive peripheral artery disease.

The details: - Prevencio described HART PAD as part of its scalable HART AI-driven diagnostics platform. - The company said the new code strengthens its reimbursement infrastructure and commercial position in AI-driven blood diagnostics. - Missy Martin-Kemp, Prevencio’s chief commercial officer, said the code adds to the company’s move from diagnostics developer to commercial precision diagnostics company. - Martin-Kemp said the HART platform now spans multiple cardiovascular diseases with proprietary billing codes, growing commercial adoption, expanding clinical evidence, and increasing payer acceptance. - James L. Januzzi, MD, chief scientific officer of the Baim Institute for Clinical Research and professor of medicine at Harvard Medical School, said PAD remains substantially underdiagnosed despite affecting millions. - Januzzi said an accurate AI-powered blood test such as HART PAD could help clinicians identify disease earlier, improve risk stratification, and guide more appropriate diagnostic evaluation and preventive treatment. - Rhonda Rhyne, Prevencio’s CEO and chief translational officer, said the company is building the “Exact Sciences of AI-powered proteomic diagnostics.” - Rhyne said Prevencio’s HART platform is intended to support a pipeline of diagnostic tests across multiple disease areas and therapeutic indications. - Prevencio listed more than 35 peer-reviewed publications and scientific presentations supporting the HART platform. - Prevencio said its portfolio includes FDA Breakthrough Device Designation for HART CADhs. - Prevencio said commercial-stage HART CADhs and HART CVE have Medicare, Medicare Advantage and select commercial reimbursement. - Prevencio said the company is seeing growing commercial adoption through laboratory and health system partnerships. - Prevencio said its global intellectual property portfolio is expanding to protect AI algorithms and multiprotein diagnostics.

Between the lines: - The billing code does not guarantee sales, but it can remove a key barrier between clinical use and payer reimbursement. - Prevencio is signaling that it wants to be judged less as a single-test company and more as a broader precision diagnostics platform. - The comparison to Exact Sciences suggests the company is aiming for a category-defining commercial model, not just a product launch.

What's next: - Prevencio said it plans to keep expanding the HART platform across multiple cardiovascular diseases and other indications. - The company also pointed to continued reimbursement growth, broader clinical adoption, and further commercialization as next steps. - Prevencio said it remains focused on building long-term strategic value through new diagnostic tests and platform expansion.

The bottom line: - The fourth AMA billing code gives Prevencio another reimbursement milestone as it pushes HART PAD and the wider HART platform deeper into commercial care.